As we enter the era of personalized medicine, it is time to take a fresh look at how we evaluate new medicines and treatments for cancer, according to Donald Berry, Ph.D., professor and chair of the Department of Biostatistics and Applied Mathematics a
A study of drug costs around the world revealed proven methods that could be used to reduce costs in the United States, according to a researcher from Wake Forest University School of Medicine.
Data from one of the largest infant vaccine trials ever conducted, published in the New England Journal of Medicine (NEJM), showed GlaxoSmithKline's (GSK)
The FDA has approved a software suite developed by Dimensional Dosing Systems, Inc. for determining optimum drug dosages of insulin and many other drugs as well as combinations of drugs. Using only
Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myelom
According to a panel of experts in the U.S. cough medicines bought over the counter do little good and may in fact harm children.In guidelines issued by the American College of Chest Physicians
Human Genome Sciences has announced a license agreement with Amgen under which Amgen has acquired exclusive worldwide rights to develop and commercialize
The U.S. Food and Drug Administration (FDA) has announced the approval of the first immune globulin product for subcutaneous injection for the prevention of serious infections in patients with Primary Imm
The European Medicines Agency has received the first application for a pandemic influenza vaccine, submitted by GlaxoSmithKline Biologicals.
People with moderate to severe malaria who are too ill to take oral medication can benefit from a single dose of rectal artesunate as initial treatment, conclude authors of a study in this week's issue of THE LANCET
Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C. The MHLW will provide a priority review of the application. If approved, PEG-INTRON and REBETOL will be the first and only pegylated interferon-based combination therapy approved in Japan for treating chronic hepatitis C.
Hepatitis C is estimated to affect some 2 million people in Japan, according to MHLW. It is the leading cause in Japan of chronic liver disease, cirrhosis and hepatocellular carcinoma, and is associated with more than 30,000 deaths there annually. Hepatitis C is the most common reason for liver transplant in major world markets, including Japan, according to a study conducted by the World Health Organization (WHO).
Schering-Plough K.K. currently markets REBETOL in Japan for use in combination with INTRON(R) A (interferon alfa-2b, recombinant) Injection for chronic hepatitis C. INTRON A also is approved in Japan for use as monotherapy for hepatitis C, hepatitis B and several cancer indications.
PEG-INTRON is a longer-acting form of INTRON A that uses proprietary PEG technology developed by Enzon, Inc. of Bridgewater, N.J. PEG-INTRON, recombinant interferon alfa-2b linked to a 12,000 dalton polyethylene glycol (PEG) molecule, is a once-weekly therapy that is designed to achieve an effective balance between antiviral activity and elimination half-life. Schering-Plough holds an exclusive worldwide license to PEG-INTRON.
INTRON A is a recombinant version of naturally occurring alpha interferon, which has been shown to exert both antiviral and immunomodulatory effects. Schering-Plough markets INTRON A for 16 major antiviral and anticancer indications worldwide.
REBETOL is an oral formulation of ribavirin, a synthetic nucleoside analog. Schering-Plough has worldwide rights to market oral ribavirin for hepatitis C through a licensing agreement with Valeant Pharmaceuticals International, formally ICN Pharmaceuticals, of Costa Mesa, Calif.